Mirum to buy Bluejay for up to $820m in rare liver disease push
The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.
Therapy Area
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
Crescent and Kelun-Biotech swap cancer asset rights in double deal
WHO backs use of GLP-1RAs for weight loss despite shortage warning
“Sharp” funding cuts disrupt PrEP access to millions of HIV patients
Dupixent gains chronic spontaneous urticaria indication in Europe
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
